Forshing Lui | Neurology | Best Researcher Award

Posted on by sciencefather

Prof. Forshing Lui | Neurology | Best Researcher Award

Dr. For-Shing Lui, a U.S. citizen and licensed neurologist in California, the UK, and Hong Kong, is an esteemed academic and clinician with over four decades of international experience in neurology and internal medicine, currently serving as Professor of Neurology at California Northstate University College of Medicine (CNUCOM), where he contributes significantly to medical education, curriculum development, and professional regulatory boards.

Profile

Education 🎓

Dr. Lui completed his M.B.B.S. from the University of Hong Kong in 1978, followed by an internal medicine residency (1978–1982) at the same institution; he then undertook neurology fellowship training at Newcastle General Hospital, UK (1982–1984), and a neurology residency at UC Davis (1995–1999), also serving as Chief Resident; his qualifications include being a Diplomate of the American Board of Psychiatry and Neurology, Fellow of the Royal College of Physicians (Edinburgh), Fellow of the Hong Kong Academy of Medicine, and Fellow of the American Academy of Neurology.

Experience 👨‍🏫

Dr. Lui has served as Expert Consultant and Reviewer for the Medical Board of California, Professor and Course Director at CNUCOM since 2014, Chair of Clinical Sciences, and Vice Chair of Education; formerly, he was Staff Neurologist and Chief of Neurology at Kaiser Permanente, Clinical Professor at UC Davis, and practiced as a neurologist and internist in Hong Kong; his roles spanned clinical practice, academic leadership, curriculum design, quality assurance, and international consultancy.

Awards & Recognitions 🏅

Dr. Lui received the 2022 A.B. Baker Teacher Recognition Award from the American Academy of Neurology, the ITLE University Distinguished Teacher Award in 2021, and multiple CNUCOM Professor of the Year Awards (2019–2023); his national recognitions include listings in America’s Top Physicians and Sacramento Magazine’s Top Doctors; he won the Croucher Fellowship (1982), John Anderson Gold Medal (1978), and several medical school scholarships for academic excellence, including the Li Shu Fan Prize in Pharmacology.

Research Interests 🔬

Dr. Lui’s academic and clinical interests lie in neurology education, vascular neurology, neuroimaging, and multiple sclerosis, with a deep commitment to medical pedagogy and curriculum leadership; his research integrates neurodiagnostic techniques with clinical neurology, particularly in imaging-based teaching, and he has presented regularly at neuroradiology conferences and contributed to educational innovation in neurology training at both Kaiser Permanente and CNUCOM, reflecting a lifelong dedication to mentoring, patient care, and advancing neurologic knowledge.

Publications

Pin Wang | Neuroimmunology | Best Researcher Award

Posted on by sciencefather

Dr. Pin Wang | Neuroimmunology | Best Researcher Award

Dr. Pin Wang, a female medical doctor and postdoctoral researcher, is an Associate Chief Physician in Neurology at the Second Hospital of Shandong University. She earned her PhD in Neurology from Shandong University in 2009 and was a visiting scholar at the NIH, USA. She specializes in neuroimmunology, focusing on multiple sclerosis and related disorders. Dr. Wang has led research funded by the Shandong Natural Science Foundation and the Department of Education, with multiple SCI-indexed publications.

Profile

Education 🎓

Dr. Wang obtained her PhD in Neurology from Shandong University School of Medicine in 2009. From 2012 to 2013, she trained at the National Institute of Neurological Disorders and Stroke (NINDS), NIH, under Dr. Bibiana Bielekova, focusing on immune-mediated neurological diseases. Her education integrates clinical neurology, research, and teaching, positioning her as an expert in demyelinating diseases and neuroimmune disorders.

Experience 👨‍🏫

Dr. Wang has extensive experience in neurology, combining clinical practice, teaching, and research. She worked at NIH, studying neuroimmune disease mechanisms and participated in the FDA-approved daclizumab clinical trials for multiple sclerosis. She is an Associate Chief Physician at Shandong University’s Second Hospital and actively contributes to patient care, student training, and neurological research, particularly in neuroimmunology.

Research Interests 🔬

Dr. Wang specializes in multiple sclerosis, neuromyelitis optica, myelitis, optic neuritis, acute disseminated encephalomyelitis, and myasthenia gravis. Her research explores immune-mediated neurological diseases, oxidative stress in demyelination, and environmental neurotoxins in neurodegenerative disorders like Alzheimer’s disease.

Dr. Wang has received funding from the Shandong Natural Science Foundation and the Department of Education for her research in neurological disorders. Her contributions to neuroimmunology have been recognized through multiple SCI publications and conference presentations. She plays an active role in professional neurology and immunology committees in Shandong Province.

Publications 📚

Carmela Conte | Neurodegenerative diseases | Best Researcher Award

Posted on by sciencefather

Prof Dr. Carmela Conte | Neurodegenerative diseases | Best Researcher Award

 

Profile

Education

Carmela Conte obtained her Master’s degree in Biological Sciences from the University of Perugia on November 3, 1994. She then pursued a Ph.D. in Medical Embryology through a joint program between the Universities of Perugia and Ferrara, completing it between December 30, 1996, and January 19, 2000. Following this, she specialized in Chemistry and Food Technology at the University of Perugia, earning her specialization between November 1, 2000, and November 1, 2002. Most recently, on September 29, 2023, she received National Habilitation as an Associate Professor in Biochemistry. She currently serves as an Aggregate Professor in her field.

Work experience

Since September 7, 2007, Carmela Conte has been serving as an Aggregate Professor in Biochemistry at the University of Perugia, where she teaches courses in General and Systematic Biochemistry, Medical Applied Biochemistry, and Molecular Biology. In addition to her teaching responsibilities, she participated in a Teaching and Training Mobility Program at VUMC Medical University of Amsterdam from June 24 to July 5, 2019, where she worked on a research project investigating the role of Toll-like receptors in Parkinson’s disease. She has been a member of the European Society for Neurochemistry since 2007 and, since March 17, 2022, has also been affiliated with the International Parkinson and Movement Disorder Society.

Research Activity

Carmela Conte’s research focuses on neurodegenerative diseases, with particular emphasis on animal models, signal transduction, molecular biology, and cell biology. Her specific research topics include the role of Toll-like receptors in Parkinson’s disease, neuroinflammation, synucleinopathies, oxidative stress, and Parkinson’s disease. Since September 7, 2007, she has been actively involved in editorial work, serving as a Reviewer Editor for Frontiers in Neuroscience (Neurodegeneration section) and as an ad hoc reviewer for several journals, including Amino Acids, The Cerebellum, Free Radical Research, Biomolecules, PLOS One, Experimental Gerontology, Molecules, Cells, Neurochemical Research, Neuroscience, Pharmacological Reports, International Journal of Molecular Sciences, Viruses, and the Journal of Biotechnology. Additionally, she has been a Guest Editor for Molecules and Cells, overseeing special issues and topic collections on neurodegenerative diseases. She has presented her research at numerous scientific meetings and conferences, including the 2009 Meeting of the European Society for Neurochemistry in Leipzig, the 2019 European Biotechnology Congress in Valencia, the 2021 European Biotechnology Congress in Sofia, the 2022 National Meeting of the Sphingolipid Club, and the 2023 Meeting of Parkinson’s Disease and Movement Disorders, where she discussed findings related to Toll-like receptor 4, alpha-synuclein accumulation, and sphingomyelinase activity in Parkinson’s disease models.

Publication

Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

Posted on by sciencefather

Dr. Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

 

 

Profile

Education

He completed his education at Org. Kenan Evren School from 2000 to 2008, followed by Gaziantep Anadolu High School from 2008 to 2012. He then pursued his medical training at Hacettepe University Faculty of Medicine from 2012 to 2018. After earning his medical degree, he continued his specialization in Plastic, Reconstructive, and Aesthetic Surgery as a resident at Hacettepe University Faculty of Medicine from November 2018 to February 2024. In April 2024, he joined Ankara Research and Training Hospital, where he continues to work in the Department of Plastic, Reconstructive, and Aesthetic Surgery.

 

Work experience

He has participated in various courses and workshops to enhance his expertise in plastic, reconstructive, and aesthetic surgery. He attended the Resident Ethics Course at Hacettepe University’s Department of History of Medicine and Medical Ethics on January 10-11, 2019. He also completed the 5th Basic Residency School organized by the Turkish Society of Plastic, Reconstructive, and Aesthetic Surgery in Bolu, Turkey, from January 22-25, 2020. Further advancing his skills, he took part in the 15th Advanced Residency School in Antalya, Turkey, from April 20-24, 2023. Additionally, he attended the 1st Cadaver Course of Craniofacial Anomaly and Maxillofacial Surgery at Hacettepe University on September 3-4, 2022, and the 1st Cadaver Course of Orthognathic Surgery at Koc University Hospital in Istanbul, Turkey, on September 7-8, 2022.

In addition to his clinical and surgical training, he has contributed to academic literature by co-authoring book chapters. He co-wrote Age-Related Changes in Trunk Aesthetics in Beauty, Aging, and Anti-Aging (1st ed., Elsevier, 2022) alongside G. G. Üstün and S. Yıldızdal. He also contributed to Dudak ve Damak Yarıkları Hacettepe Ekip Yaklaşım, co-authoring “Apert and Crouzon Syndrome” with İbrahim Vargel.

Awards

He has achieved remarkable academic success, securing 16th place in the National Examination for Specialty in Medicine among over 18,000 participants. Additionally, he ranked 571st in the National Student Selection and Placement Examination out of more than 2 million candidates.

He has actively participated in national meetings within his field, contributing to discussions and advancements in plastic, reconstructive, and aesthetic surgery. He attended the 41st National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Samsun, Turkey, from October 26-30, 2019. He also participated in the National Turkish Plastic Reconstructive and Aesthetic Surgery Eastern Mediterranean Meeting on Cleft Lip and Palate, held in Gaziantep, Turkey, from February 7-9, 2020. Furthermore, he attended the 43rd National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Antalya, Turkey, from November 10-14, 2021.

 

Publication

Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Posted on by sciencefather

Prof Dr. Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Michal Schwartz (born 1 January 1950) is a professor of neuroimmunology at the Weizmann Institute of Science. She is active in the field of neurodegenerative diseases, particularly utilizing the immune system to help the brain fight terminal neurodegenerative brain diseases, such as Alzheimer’s disease and dementia.[3][1]

Schwartz’s studies have shown that the immune system supports a healthy brain’s function and is vital for healing and protecting the brain in case of injury or disease.[4]

Schwartz coined the term protective autoimmunity[5] and discovered roles for immune cells in repair and neurogenesis. She has been the elected chair of the International Society of Neuroimmunology (ISNI) since 2016.[6]

In 2023 Schwartz received the honorary Israel Prize for Life Sciences.

 

Profile

Education

Schwartz gained her Bachelor of Science in chemistry at the Hebrew University of Jerusalem in 1972. She received her Ph.D in Immunology in 1977 at the Weizmann Institute of Science, where she would later spend the majority of her career. She also spent time at the University of Michigan, Ann Arbor, researching nerve regeneration.[when?

 

Work experience

At the Weizmann Institute, she progressed from senior scientist in the Department of Neurobiology to full professor in 1998, and was then awarded the Maurice and Ilse Katz Professorial Chair in Neuroimmunology in 2016.[7] Schwartz’s work in neuroimmunology has encompassed a wide range of pathologies in the central nervous system (CNS), including injury, neurodegeneration, mental dysfunction, and aging. She coined the term protective autoimmunity and demonstrated the role of immune cells such as macrophages and T cells in spinal cord repair. She also identified specific brain areas for ‘cross talk’ between the CNS and the immune system. This cross-talk is important for recruiting immune cells and maintaining a healthy brain, and the disruption of this cross-talk can play a role in brain aging and neurodegenerative disease. She also showed this role in pregnancy and fetal brain development, where immune disruption in the mother can be linked to neurodevelopmental disorders in their children. Another focus of her work has been on repurposing cancer immunotherapies such as PD-1 blockers to treat neurodegenerative disorders, such as Alzheimer’s disease.

Macrophages

The Schwartz team discovered that bone marrow-derived macrophages are needed for central nervous system (CNS) repair. The brain-resident myeloid cells (the microglia), and infiltrating monocyte-derived macrophages are not redundant populations, despite their myeloid phenotype, and display distinct functions in resolution of brain inflammation.[8][9][10]

Autoimmunity

In her research, Schwartz discovered that the ability to cope with sterile CNS injuries requires support in the form of an adaptive immune response mediated by CD4+ T cells that recognize CNS antigens. She coined the concept of protective autoimmunity, to distinguish this response from autoimmune disease, in which the anti-self response escapes control. Over the years, it became clear that adaptive immunity is needed to facilitate the recruitment of immunoregulatory cells, including bone marrow-derived macrophages and FoxP3 regulatory T cells, though the balance between regulatory T cells and effector memory cells is different in the periphery versus the brain.[11][12][13]

Brain Homeostasis

Schwartz’s team discovered the role of adaptive systemic immune cells, and specifically T cells recognizing brain antigens (Protective autoimmune T cells), in supporting the cognitive capacity of the healthy brain, for lifelong neurogenesis, and functional brain plasticity. These observations paved the way for numerous additional discoveries in which the brain-immune axis was described.[14][15][16]

The Choroid Plexus

Schwartz’s team identified the brain’s choroid plexus (CP) within the blood-cerebrospinal fluid barrier as an immunological interface between the brain and the immune system. It serves as a niche that hosts immune cells, and as a physiological entry gate for leukocytes. Focusing on this unique niche within the brain led the Schwartz group to propose that IFN-γ holds the key to regulating CP gateway activity. Her team further showed that in brain aging and neurodegenerative diseases (studied using both mouse models and human samples), dysfunction of this interface is determined both by signals originating in the brain, and signals from the aged immune system, which led to the identification of Type-I Interferon (IFN-I) at the CP as a negative player, affecting the fate of the aging brain in general, and of microglia, in particular. A similar IFN-I signature at the CP was subsequently discovered by others in Alzheimer’s disease and in the postmortem brains of infected patients who died from COVID-19.[17][14][10]

Immunotherapy

The discovery that adaptive immunity plays a key role in brain function and repair, the need for bone marrow-derived macrophages to resolve local brain inflammation, the fact that Alzheimer’s disease (AD) and all forms of dementia are mainly age-related diseases, and the fact that the immune system is particularly affected by aging all led Schwartz to propose a new treatment for combating dementias. Schwartz suggested empowering systemic immunity, using a form of immunotherapy by modestly blocking the inhibitory immune checkpoint PD1/PD-L1 pathway.[citation needed] This treatment drives an immune-dependent cascade of events, that allows the harnessing of bone marrow-derived macrophages and regulatory T cells to help clear toxic factors from the diseased brain, and to arrest the local inflammation, thereby providing a comprehensive multi-factorial therapy through modification of multiple elements that go awry in AD. Schwartz’s patents for developing such immunotherapy for AD are licensed to a small Biopharma company, Immunobrain Checkpoint. The company is awaiting a clinical trial in AD patients, supported in part by the National Institute of Aging, the US National Institutes of Health, and The Alzheimer’s Association.[18][19][20][21][22][23]

Publication

1. Rachmian N, Medina S, Cherqui U, Akiva H, Deitch D, Edilbi D, Croese T, Salame T, Peralta Ramos
J, Cahalon L, Krizhanovsky V, Schwartz M. 2024. Senescent microglia conserved in aging and
Alzheimer’s disease exhibit elevated TREM2 protein levels. Nat Neurosci 27: 1116-24
2. Tsitsou-Kampeli A, Suzzi S, Kenigsbuch M, Satomi A, Strobelt R, Singer O, Feldmesser E, Purnapatre
M, Colaiuta SP, David E, Cahalon L, Hahn O, Wyss-Coray T, Shaul Y, Amit I, Schwartz M. 2023.
Cholesterol 24-hydroxylase at the choroid plexus contributes to brain immune homeostasis. Cell Rep
Med: 101278
3. Suzzi, S. Croese T., Ravid A., Gold O., Clark A., Medina A., Kitsberg D., Adam M., Vernon K., Kohnert
E., Shapira I., Malitsky S., Itkin M., Brandis A., Mehlman T., Salame T., Colaiuta S., Cahalon L.,Slyper
M., Greka A., Habib N., Schwartz M. 2023. N-acetylneuraminic acid links immune exhaustion and
accelerated memory deficit in diet-induced obese Alzheimer’s disease mouse model 2023. Nat. Commun.
14:1293.
4. Kenigsbuch M, Bost P, Halevi S, Chang Y, Chen S, Ma Q, Hajbi R, Schwikowski B, Bodenmiller B, Fu
H, Schwartz M*, Amit I* (equal contribution, and corresponding authors). 2022. A shared diseaseassociated oligodendrocyte signature among multiple CNS pathologies. Nat Neurosci 25: 876-86.
5. Dvir-Szternfeld R, Castellani G, Arad M, Cahalon L, Colaiuta SP, Keren-Shaul H, Croese T, Burgaletto
C, Baruch K, Ulland T, Colonna M, Weiner A, Amit I, Schwartz M. 2022. Alzheimer’s disease
modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in
mouse model of amyloidosis. Nature Aging 2: 60-73 (citations:17).
6. Ben-Yehuda H, Arad M, Peralta Ramos JM, Sharon E, Castellani G, Ferrera S, Cahalon L, Colaiuta SP,
Salame TM, Schwartz M. 2021. Key role of the CCR2-CCL2 axis in disease modification in a mouse
model of tauopathy. Mol Neurodegeneration 16: 39. (citations:20).
7. Cohen M, Giladi A, Raposo C, Zada M, Li B, Ruckh J, Deczkowska A, Mohar B, Shechter R, Lichtenstein
RG, Amit I, Schwartz M. 2021. Meningeal lymphoid structures are activated under acute and chronic
spinal cord pathologies. Life Sci Alliance 4: e202000907.
8. Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D,
Nguyen L, Marshall JL, Chen F, Zhang F, Kaplan T, Regev A, Schwartz M. 2020. Disease- associated
astrocytes in Alzheimer’s disease and aging. Nat Neurosci 23: 701-6. (citations:617).
9. Ben-Yehuda H, Matcovitch-Natan O, Kertser A, Spinrad A, Prinz M, Amit I, Schwartz M. 2020.
Maternal Type-I interferon signaling adversely affects the microglia and the behavior of the offspring
accompanied by increased sensitivity to stress. Mol Psychiatry 25: 1050-67 (Cover page).
10. Kertser A,Baruch K, Deczkowska A,Weiner A,Croese T, Kenigsbuch M,CooperI, Tsoory M,Ben- Hamo
S, Amit I, Schwartz M. 2019. Corticosteroid signaling at the brain-immune interface impedes coping with
severe psychological stress. Sci Adv 5: eaav4111. (citations:32).
11. Rosenzweig N, Dvir-Sternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P,
Cahalon L, Kertser A, Baruch K, Amit I, Weiner A, Schwartz M. 2019. PD-1/PD-L1 checkpoint blockade
harnesses monocyte-derived macrophages to combat cognitive impairment in a mouse model of tauassociated dementia. Nat Commun. 10: 465. (citations:141).
12. Deczkowska A, Matcovitch-Natan O, Tsitsou-Kampeli A, Ben-Hamo S, Dvir-Szternfeld R, Spinrad A,
Singer O, David E, Winter RD, Smith KL, Kertser A, Baruch K, Rosenzweig N, Terem A, Prinz M,
Villeda S, Citri A, Amit I, Schwartz M. 2017. Mef2C restrains the microglial inflammatory response and
is lost in brain ageing in an IFN-I-dependent manner. Nat Commun 8: 717. (citations:212).
13. Cohen M, Ben-Yehuda H, Porat Z, Raposo C, Gordon S, Schwartz M. 2017. Newly formed endothelial
2
cells regulate myeloid cell activity following spinal cord injury via expression of CD200 ligand. J
Neurosci 37: 972-85.

said Pournaghash-tehrani | Neuroscience | Best Faculty Award

Posted on by sciencefather

Dr. said Pournaghash-tehrani | Neuroscience | Best Faculty Award

 

Profile

  • Googlescholar
  • Researchgate

Education

Said Pournaghash-Tehrani earned his Doctor of Philosophy in Psychology in 1993 from The American University in Washington, D.C., where he also completed his Master of Arts in Psychology in 1990. He holds a Bachelor of Science in Distributive Science from the same institution, which he obtained in 1986. Fluent in English and German, he also has familiarity with French. He can be reached via email at spournaghash@yahoo.com or by telephone at 011-98-09122074388.

Work experience
  • Said Pournaghash-Tehrani has extensive academic and research experience in psychology. He served as a Research Associate in 2001 at the Department of Pharmacology and Experimental Therapeutics, Loyola University’s Stritch School of Medicine in Chicago, Illinois. In 2002, he took a sabbatical as a researcher at the Department of Psychology, Carleton University in Ottawa, Canada, focusing on cross-cultural studies related to Iranian attitudes towards the West. Since 2002, he has been an Assistant Professor in the Department of Psychology at Tehran University, having previously held the same position at Azzahra University in Tehran from 1996 to 2001. Additionally, he was a member of the Scientific Council on Energy and Economic Studies at the Institute for International and Political Studies (IPIS) from 1998 to 2000, where he also worked as a political researcher. His early academic career included serving as a Teaching and Research Assistant at The American University’s Department of Psychology from 1987 to 1990, where he contributed to courses such as Introduction to Psychology, Neuroscience Seminar, Psychopharmacology, Neuropsychology, Biological Basis of Behavior, and Learning and Behavior.

Books

–Fundamentals of Clinical Psychopharmacology, (2007); Samt Publications
-Drugs and Behavior, (2004); Samt Publications.
-Physiological Psychology, Tehran University Publication.
-Intimacy; Alzahra University Publication.
-Theories of Addiction, Alzahra University Publication.

Conference Presentations

Said Pournaghash-Tehrani has contributed extensively to neuroscience and psychology research, presenting his findings at prestigious conferences such as the Society for Neuroscience and the Eastern Psychological Association. His work has focused on drug discrimination learning, conditioned taste aversion, and the effects of opioids and their antagonists. In 1987, he co-authored studies assessing the discriminative stimulus properties of naloxone and the failure of cholecystokinin to counteract morphine sulfate’s effects. His later research explored the antagonism of morphine stimuli, the role of buprenorphine in opiate-naive and dependent animals, and the impact of RO15-4513 on ethanol-induced taste aversion. He has collaborated with notable researchers, including A.L. Riley, contributing to investigations on diazepam exposure and behavioral toxicology. His presentations in New Orleans, Washington, D.C., Boston, and other major research venues highlight his significant role in advancing psychopharmacology and behavioral neuroscience.

Publication